Empagliflozin: A Review in Type 2 Diabetes
Abstract
Empagliflozin (Jardiance®), a potent, highly selective, sodium glucose cotransporter-2 (SGLT2) inhibitor, is an effective and generally well tolerated antihyperglycaemic agent approved for the treatment of adults with type 2 diabetes (T2D) in the EU, USA and Japan, among other parts of the world. As with other members of its class, empagliflozin offers the convenience of once-daily oral administration and carries a low inherent risk of hypoglycaemia as a result of its insulin-independent mechanism of action, enabling it to be used as monotherapy and as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with T2D. Beyond lowering glucose, empagliflozin exerts a favourable effect on a number of nonglycaemic outcomes, including modest reductions in bodyweight and blood pressure. As an adjunct to standard care, it demonstrated cardioprotective and renoprotective properties largely independent of glycaemic control in patients with T2D and established cardiovascular disease (CVD) in a mandated cardiovascular (CV) outcomes trial (EMPA-REG OUTCOME). Empagliflozin is generally well tolerated as monotherapy or as add-on therapy and, unlike canagliflozin (the only other SGLT2 inhibitor that has so far shown CV and renal benefits), it has not been associated with an increased risk of amputation or bone fractures. In conclusion, empagliflozin is a valuable treatment option for the management of T2D.…
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.